Lung cancer symptoms extend beyond respiratory issues and can manifest as shoulder pain. Tumors pressing on nearby nerves can ...

small cell lung cancer, NSCLC spreads and grows more slowly. Some people may not experience symptoms in the earliest stages, but over time, symptoms can become more serious. Early signs like ...

Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

Doctors stage non-small cell lung cancer (NSCLC) according to how far it has progressed. Stages range from occult (or hidden) cancer to stage 4 cancer, in which multiple organs may be affected.

Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...

Lung cancer is the one of the most common types of cancer doctors diagnose each year in the U.S. The most common kind of lung cancer is non-small-cell lung cancer (NSCLC). It makes up around 84% ...

Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint ...

Small-cell lung cancer (SCLC) is the most aggressive type of lung cancer. Each year in the U.S., about 30,000 to 35,000 people are diagnosed with it. For most, it has already spread to distant ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...